Clinical trials: Arterial Obstructive Diseases
ACS, Acute Coronary Syndrome
Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge
The aim of this international study is to describe the short- and long-term (i.e. up to 2 years following the index event) antithrombotic management patterns (AMPs) in patients hospitalized for acute coronary syndromes (ST…
- Conditions
- ACS, Acute Coronary Syndrome, Myocardial Infarction, Unstable Angina
- Trial name
- EPICOR (NCT01171404)
- Where
- 410 sites in Argentina, Belgium and 18 more
- Volunteers
- 10,568 people
- Sponsor
- AstraZeneca
Peripheral Artery Disease
Korean Post-market Registry Assessing the Clinical Use and Safety of the Lutonix DCB in Femoropopliteal Arteries
The purpose of the registry is to assess the clinical use and safety of the LUTONIX Drug Coated Balloon Catheter in a heterogeneous patient population in real world clinical practice.
- Trial name
- NCT02717104
- Where
- 16 sites in South Korea
- Volunteers
- 249 people
- Sponsor
- C. R. Bard
Arterial Occlusive Diseases
Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery
The purpose of this study is to directly compare the safety and efficacy of intra-thrombus alfimeprase 0.3 mg/kg with placebo in acute peripheral arterial occlusion (PAO) as measured by a 30 day open vascular free surgery rate.
- Trial name
- NCT00338585
- Testing
- alfimeprase
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- ARCA Biopharma, Inc.
Peripheral Artery Disease
A Study of Below The Knee Arteries' Stenosis or Occlusion Treated With LEGFLOW OTW
To evaluate the safety and efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) compared to the PTA catheter (AMPHIRION DEEP) in treatment of stenosis or occlusion in below the knee artery.
- Trial name
- NCT02962232
- Testing
- Paclitaxel Releasing Peripheral Balloon Dilatation Catheter, PTA catheter
- Where
- 19 sites in China
- Volunteers
- 172 people
- Sponsor
- ZhuHai Cardionovum Medical Device Co., Ltd.
Coronary Restenosis
Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period
Interventional, prospective, non-randomized, non-comparative, open and multicentric study of patients with everolimus-eluting stent " Xience V® " implanted in the treatment of restenosis in non-coated metallic stent (BMS in-stent…
- Trial name
- XERES (NCT00882219)
- Testing
- Xience V®
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, DCB
TReAtmeNt of Small Coronary Vessels: MagicTouch Sirolimus Coated Balloon
The study is a prospective, multinational (Italy, Ireland and UK), multicenter, randomised Clinical Trial that compares the efficacy and performance of two drug coated balloon (DCB), the MAGIC TOUCH sirolimus coated balloon…
- Trial name
- TRANSFORM I (NCT03913832)
- Testing
- sirolimus drug coated balloon (SCB), paclitaxel releasing coronary balloon catheter
- Where
- 6 sites in Ireland, Italy and 1 more
- Volunteers
- 121 people
- Sponsor
- Concept Medicals BV
Oxidative Stress, Coronary Artery Disease
Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.
The purpose of this study is to determine the effects of pioglitazone, once daily (QD), on heart functioning before, during and after stent implantation.
- Conditions
- Oxidative Stress, Coronary Artery Disease, Type 2 Diabetes
- Trial name
- NCT00771004
- Testing
- Pioglitazone
- Where
- 7 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Takeda
Coronary Artery Disease
Elixir Medical Clinical Evaluation of the DESolve Myolimus Eluting Bioresorbable Coronary Stent System - DESolve I Trial
This prospective, consecutive enrolment, single-arm study will enroll up to 15 patients with single de novo, Type A lesions < 10 mm in length and located in a native coronary artery with a reference vessel diameter of 2.75 mm …
- Trial name
- NCT02086006
- Testing
- DESolve Novolimus Eluting Bioresorbable Coronary Scaffold
- Where
- 3 sites in Belgium, New Zealand
- Volunteers
- 16 people
- Sponsor
- Elixir Medical Corporation
Peripheral Arterial Disease
BioMimics 3D Stent Clinical Investigation: The Mimics Study
Primary purpose of the Mimics Study is to evaluate the safety and performance of the BioMimics 3D Stent System in the treatment of symptomatic SFA/proximal popliteal disease.
- Trial name
- Mimics (NCT02163863)
- Testing
- Femoropopliteal stenting
- Where
- Germany
- Volunteers
- 86 people
- Sponsor
- Veryan Medical Ltd.
Acute Coronary Syndrome, Myocardial Infarction
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- COGENT-1 (NCT00557921)
- Testing
- CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
- Where
- 491 sites in United States, Australia and 14 more
- Volunteers
- 5,000 people
- Sponsor
- Cogentus Pharmaceuticals
Arteriovenous Fistula, Arteriovenous Graft
FLEX FIRST Registry Research Protocol
Prospective, observational study evaluating the clinical use and outcomes of the FLEX Vessel Prep (VP) system in arteriovenous fistulae or grafts presenting with clinical or hemodynamic abnormalities following 12 months post…
- Conditions
- Arteriovenous Fistula, Arteriovenous Graft, Fistula, Arterial Occlusive Diseases
- Trial name
- NCT05616104
- Testing
- FLEX Vessel Prep System
- Where
- 4 sites in United States
- Volunteers
- 130 people
- Sponsor
- VentureMed Group Inc.
Peripheral Arterial Disease
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.
- Trial name
- ATTAIN-PAD (NCT07223593)
- Testing
- Orforglipron
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 1,205 people
- Sponsor
- Eli Lilly and Company
Sarpogrelate, Blood Viscosity
A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease
This study is to compare the effects of sarpogrelate sustained release /aspirin combination therapy versus aspirin on blood viscosity in the patients with peripheral arterial disease and coronary artery disease
- Conditions
- Sarpogrelate, Blood Viscosity, Peripheral Arterial Disease, Coronary Artery Disease
- Trial name
- NCT05730621
- Testing
- Sarpogrelate Sustained Release/Aspirin, Aspirin
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Yuhan Corporation
Coronary Artery Disease
Long-Term Follow-up Study of Patients Who Received PB127 Ultrasound Imaging Agent
The purpose of this study is to collect longer term follow-up information concerning health and survival on selected patients who received PB127 for injectable suspension in the pivotal trial (127-014).
- Trial name
- NCT00584714
- Where
- 39 sites in United States
- Volunteers
- 300 people
- Sponsor
- Point Biomedical
Thoracic Aortic Aneurysm, Penetrating Aortic Ulcers (PAUs)
MBA Early Feasibility Study
The MBA 25-04 study is a prospective, multicenter, non-randomized, single-arm, early feasibility study designed to assess the initial safety of the MBA device through five years following the index endovascular procedure.
- Conditions
- Thoracic Aortic Aneurysm, Penetrating Aortic Ulcers (PAUs), Thoracic Aortic Dissection, Pseudoaneurysm
- Trial name
- NCT07564375
- Testing
- GORE® Multibranch Arch Endoprosthesis, GORE® Ascending Stent Graft
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- W.L.Gore & Associates
Coronary Artery Disease
TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions
TAXUS ATLAS is a global, multi-center, single-arm, non-inferiority trial comparing results from patients treated with the TAXUS Liberté stent to an historical TAXUS Express control.
- Trial name
- NCT00371709
- Testing
- TAXUS Liberté-SR, TAXUS™ Express
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 871 people
- Sponsor
- Boston Scientific Corporation
Carotid Artery Stenosis, Carotid Artery Diseases
Protection Against Emboli During Carotid Artery Stenting Using the Neuroguard IEP System
A prospective, multicenter single-arm, open label study to evaluate the safety and effectiveness of the Neuroguard IEP System for the treatment of carotid artery stenosis in subjects at elevated risk for adverse events following…
- Conditions
- Carotid Artery Stenosis, Carotid Artery Diseases, Carotid Stenosis
- Trial name
- PERFORMANCE II (NCT04201132)
- Testing
- Carotid artery stenting with Neuroguard IEP System
- Where
- 38 sites in United States, Bulgaria and 4 more
- Volunteers
- 305 people
- Sponsor
- Contego Medical, Inc.
Peripheral Arterial Disease, Critical Limb Ischemia
Tibiopedal Access for Crossing of Infrainguinal Artery Occlusions
The objective of this prospective, non-randomized, multicenter, post-market, observational study is to compile clinical data on percutaneous techniques used to obtain tibiopedal access and to cross infrainguinal arterial…
- Trial name
- NCT01609621
- Testing
- Retrograde tibiopedal arterial access
- Where
- 11 sites in United States, Germany and 1 more
- Volunteers
- 199 people
- Sponsor
- Cook Group Incorporated
Intermittent Claudication
Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers
The study is designed to evaluate the bioequivalency between the test formulations of extended-release tablet of cilostazol (PMR) administered once-daily and the reference formulation of immediate-release tablet of cilostazol…
- Trial name
- NCT03480321
- Testing
- Cilostazol 100 mg, PMR 150 mg, PMR 200 mg
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Coronary Artery Disease
Phase IV Study to Compare Efficacy and Safety of Plavix 75mg With Astrix 100mg and Closone
The Aim of this study is to prove non-inferiority of Closone to the Combination treatment of Plavix with Astrix.
- Trial name
- NCT01765452
- Testing
- Closone, Plavix with Astrix
- Where
- 7 sites in South Korea
- Volunteers
- 285 people
- Sponsor
- HK inno.N Corporation